Skip to main content

LIVE

OverviewAnalystsInstitutionalElite HoldersEarningsNews
SLS

SELLAS Life Sciences Group, Inc.

SLS

NASDAQ·Healthcare·Biotechnology·Mkt cap $2.6B

$13.86

▲ +1.17%

P/E

-65.19

Mkt Cap

$2.6B

52-Wk Range

$1.39–$15.88

52-Week Range

$1.39 - $15.88

P/E

-65.19

Fwd P/E

-67.61

Beta

2.52

Div Yield

0.00%

Avg Vol

8.7M

Shares Out

142.4M

Mkt Cap

$2.6B

Price action

Price chart

Up 629.5% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Proprietary peptide immunotherapy platform targeting validated cancer antigens
  • Strategic partnership with Merck providing development support and credibility
  • Late-stage clinical pipeline with Phase III data potential in high-need indications
  • Focus on combination therapy approaches enhancing efficacy and market potential
▼

Bear Case

1 risk

  • High volatility (beta 2.5). Larger-than-normal price swings expected.

Growth

Stable outlook

Phase III trial results for GPS in acute myeloid leukemia expected to drive regulatory approval pathway

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Hot

+73.7% over 3m

Quality

Loss-making

Solid business

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Nov 11, 2026

“
Q3 26 RECAP

AUG 11, 2026

Reported EPS of -$0.05 vs -$0.05 consensus (-11.1% surprise).

EPS miss

EPS surprise · last 4Q

0 of 1 beats

Estimate

Actual

Q3 26

-11.1%

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

Q2 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

1 analyst · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

1

100%

Hold

0%

Sell

0%

Median Price Target

—

Latest: Alliance Global Partners · Aug 12, 2026

View full analyst page →

vs Industry

How SLS stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.